Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates

Journal of Neurochemistry

Volumn 105, Issue 5, 2008, Pages 1861-1872

  Perez, Xiomara A ^a   Parameswaran, Neeraja ^a   Huang, Luping Z ^a   O'Leary, Kathryn T ^a   Quik, Maryka ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

Compensation; Dopamine release; MPTP; Non human primate; Parkinson's disease; Voltammetry

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN SLICE; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; FEMALE; MONKEY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; STRIATE CORTEX; SYNAPTOSOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DOPAMINE; ELECTRIC STIMULATION; FEMALE; PARKINSON DISEASE, SECONDARY; PRESYNAPTIC TERMINALS; SAIMIRI; SUBSTANTIA NIGRA;

ANIMALIA; PARKINSONIA; PRIMATES;

EID: 43549110484     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05268.x     Document Type: Article

References (55)

1. Alexander G. M., Schwartzman R. J., Brainard L., Gordon S. W. Grothusen J. R. (1992) Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res. 588, 261 269.
2. Bergstrom B. P. Garris P. A. (2003) 'Passive stabilization' of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat. J. Neurochem. 87, 1224 1236.
3. Bergstrom B. P., Schertz K. E., Weirick T., Nafziger B., Takacs S. A., Lopes K. O., Massa K. J., Walker Q. D. Garris P. A. (2001) Partial, graded losses of dopamine terminals in the rat caudate-putamen: an animal model for the study of compensatory adaptation in preclinical parkinsonism. J. Neurosci. Methods 106, 15 28.
4. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K. Seitelberger F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415 455.
5. Betarbet R. Greenamyre J. T. (2004) Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp. Neurol. 189, 393 403.
6. Bezard E., Boraud T., Bioulac B. Gross C. E. (1999) Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11, 2167 2170.
7. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B. Gross C. E. (2000) Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur. J. Neurosci. 12, 2892 2900.
8. Bezard E., Crossman A. R., Gross C. E. Brotchie J. M. (2001a) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J. 15, 1092 1094.
9. Bezard E., Ravenscroft P., Gross C. E., Crossman A. R. Brotchie J. M. (2001b) Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6- tetrahydropyridine monkeys. Neurobiol. Dis. 8, 343 350.
10. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A. R., Bioulac B., Brotchie J. M. Gross C. E. (2001c) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853 6861.
11. Bezard E., Gross C. E. Brotchie J. M. (2003) Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26, 215 221.
12. Chen B. T. Rice M. E. (2001) Novel Ca2 + Dependence and Time Course of Somatodendritic Dopamine Release: Substantia Nigra versus Striatum. J. Neurosci. 21, 7841 7847.
13. Coates K. M. Flood P. (2001) Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br. J. Pharmacol. 134, 871 879.
14. Cragg S. J., Nicholson C., Kume-Kick J., Tao L. Rice M. E. (2001) Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J. Neurophysiol. 85, 1761 1771.
15. Elsworth J. D. Roth R. H. (1997) Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp. Neurol. 144, 4 9.
16. Elsworth J. D., Deutch A. Y., Redmond Jr. D. E., Taylor J. R., Sladek Jr. J. R. Roth R. H. (1989) Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience 33, 323 331.
17. Flood P. Krasowski M. D. (2000) Intravenous anesthetics differentially modulate ligand-gated ion channels. Anesthesiology 92, 1418 1425.
18. Galvan A. Wichmann T. (2007) GABAergic circuits in the basal ganglia and movement disorders. Prog. Brain Res. 160, 287 312.
19. Garris P. A., Walker Q. D. Wightman R. M. (1997) Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res. 753, 225 234.
20. Gerhardt G. A., Cass W. A., Hudson J., Henson M., Zhang Z., Ovadia A., Hoffer B. J. Gash D. M. (1996) In vivo electrochemical studies of dopamine overflow and clearance in the striatum of normal and MPTP-treated rhesus monkeys. J. Neurochem. 66, 579 588.
21. Hornykiewicz O. (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18, 925 964.
22. Hornykiewicz O. (1975) Brain monoamines and parkinsonism. Natl Inst. Drug Abuse Res. Monogr. Ser. 3, 13 21.
23. Hornykiewicz O. (2001) Chemical neuroanatomy of the basal ganglia - normal and in Parkinson's disease. J. Chem. Neuroanat. 22, 3 12.
24. Huot P. Parent A. (2007) Dopaminergic neurons intrinsic to the striatum. J. Neurochem. 101, 1441 1447.
25. John C. E., Budygin E. A., Mateo Y. Jones S. R. (2006) Neurochemical characterization of the release and uptake of dopamine in ventral tegmental area and serotonin in substantia nigra of the mouse. J. Neurochem. 96, 267 282.
26. Langer L. F. Graybiel A. M. (1989) Distinct nigrostriatal projection systems innervate striosomes and matrix in the primate striatum. Brain Res. 498, 344 350.
27. Lowry O. H., Rosebrough N. J., Farr A. L. Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265 275.
28. McCallum S. E., Parameswaran N., Bordia T., McIntosh J. M., Grady S. R. Quik M. (2005) Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. Mol. Pharmacol. 68, 737 746.
29. McCallum S. E., Parameswaran N., Perez X. A., Bao S., McIntosh J. M., Grady S. R. Quik M. (2006) Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates. J. Neurochem. 96, 960 972.
30. Michael D. J. Wightman R. M. (1999) Electrochemical monitoring of biogenic amine neurotransmission in real time. J. Pharm. Biomed. Anal. 19, 33 46.
31. Morissette M., Grondin R., Goulet M., Bedard P. J. Di Paolo T. (1999) Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 72, 682 692.
32. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., Arbizu J. Gimenez-Amaya J. M. (2002) The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol. Sci. 17, 51 55.
33. Obeso J. A., Rodriguez-Oroz M. C., Lanciego J. L. Rodriguez Diaz M. (2004) How does Parkinson's disease begin? The role of compensatory mechanisms Trends Neurosci. 27, 125 127.
34. Onn S. P., Berger T. W., Stricker E. M. Zigmond M. J. (1986) Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis. Brain Res. 376, 8 19.
35. Perez X. A., Bressler A. J. Andrews A. M. (2007) Determining serotonin and dopamine uptake rates in synaptosomes using high-speed chronoamperometry, in Electrochemical Methods for Neuroscience (Michael A. C. Borland L. M., eds pp. 103 124. CRC Press LLC, Boca Raton, FL.
36. Pifl C. Hornykiewicz O. (2006) Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem. Int. 49, 519 524.
37. Pisani A., Bernardi G., Ding J. Surmeier D. J. (2007) Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 30, 545 553.
38. Quik M., Chen L., Parameswaran N., Xie X., Langston J. W. McCallum S. E. (2006) Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci. 26, 4681 4689.
39. Quik M., Cox H., Parameswaran N., O'Leary K., Langston J. W. Di Monte D. (2007) Nicotine reduces levodopa-induced dyskinesias in monkeys with nigrostriatal damage. Ann. Neurol. 62, 588 596.
40. Roffler-Tarlov S., Sharman D. F. Tegerdine P. (1971) 3,4- dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the mouse striatum: a reflection of intra- and extra-neuronal metabolism of dopamine? Br. J. Pharmacol. 42, 343 351.
41. Singh N., Pillay V. Choonara Y. E. (2007) Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81, 29 44.
42. Snyder G. L., Keller Jr. R. W. Zigmond M. J. (1990) Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J. Pharmacol. Exp. Ther. 253, 867 876.
43. Stachowiak M. K., Keller Jr. R. W., Stricker E. M. Zigmond M. J. (1987) Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 7, 1648 1654.
44. Tassonyi E., Charpantier E., Muller D., Dumont L. Bertrand D. (2002) The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res. Bull. 57, 133 150.
45. Troyer K. P., Heien M. L., Venton B. J. Wightman R. M. (2002) Neurochemistry and electroanalytical probes. Curr. Opin. Chem. Biol. 6, 696 703.
46. Wichmann T. DeLong M. R. (1996) Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6, 751 758.
47. Wichmann T. DeLong M. R. (2003) Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. NY Acad. Sci. 991, 199 213.
48. Widnell K. (2005) Pathophysiology of motor fluctuations in Parkinson's disease. Mov. Disord. 20 (Suppl. 11 S17 S22.
49. Wightman R. M. Zimmerman J. B. (1990) Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res. Brain Res. Rev. 15, 135 144.
50. Zhang L., Zhou F. M. Dani J. A. (2004) Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol. 66, 538 544.
51. Zhou F. M., Wilson C. J. Dani J. A. (2002) Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol. 53, 590 605.
52. Zigmond M. J. (1997) Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism Neurobiol. Dis. 4, 247 253.
53. Zigmond M. J., Acheson A. L., Stachowiak M. K. Stricker E. M. (1984) Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41, 856 861.
54. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290 296.
55. Zoli M., Torri C., Ferrari R., Jansson A., Zini I., Fuxe K. Agnati L. F. (1998) The emergence of the volume transmission concept. Brain Res. Brain Res. Rev. 26, 136 147.